Certolizumab pegol in the treatment of spondyloarthritis

Certolizumab pegol in the treatment of spondyloarthritis

Spondyloarthropaties (SpA) are a second common group of inflammatory rheumatic diseases after systemic connective tissue diseases. They are a frequent cause of disability. Tumor necrosis factor α (TNF-α) plays a crucial role in the initiation and continuation of chronic inflammation in SpA patients....

Full description

Bibliographic Details
Main Author: Mariusz Korkosz
Format: Article
Language:English
Published: Termedia Publishing House 2014-09-01
Series:Rheumatology
Subjects:
ankylosing spondylitis
TNF inhibitors
inflammatory spondyloarthropaties
certolizumab pegol
Online Access:http://www.termedia.pl/Certolizumab-pegol-in-the-treatment-of-spondyloarthritis,18,23337,1,1.html

Internet

http://www.termedia.pl/Certolizumab-pegol-in-the-treatment-of-spondyloarthritis,18,23337,1,1.html

Similar Items